Maegim한국어

HLB제넥스

187420KOSDAQSector: Pharma & Biotech
₩1,570▼ 4.38%Market cap ₩51.3BAs of Jul 21, 2026 close · updated once daily
A
Grade A66.9 ptsTop 18% of 2,523 stocks
Financial strength
48.2
Growth momentum
84.5
Price attractiveness
75.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

48.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
148.1%
✗ Below median · Top 86.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
79.5%
✗ Below median · Top 83.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
2.8%
✓ Above median · Top 37.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
55.2%
✓ Above median · Top 0.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

84.5
How much did revenue grow in a year?
Revenue growth (YoY)
22.4%
✓ Above median · Top 21.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
16.0%
✓ Above median · Top 17.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
164.3%
✓ Above median · Top 10% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
119.4%
✓ Above median · Top 12.6% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

75.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
2.3x
✓ Above median · Top 0.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.25x
✓ Above median · Top 47.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15